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New-onset refractory status epilepticus (NORSE) is a rare but challenging condition 
occurring in a previously healthy patient, often with no identifiable cause. We describe 
the electro-clinical features and outcomes in a group of patients with NORSE who all 
demonstrated a typical magnetic resonance imaging (MRI) sign characterized by bilateral 
lesions of the claustrum. The group includes 31 patients (12 personal and 19 previously 
published cases; 17 females; mean age of 25 years). Fever preceded status epilepticus 
(SE) in 28 patients, by a mean of 6 days. SE was refractory/super-refractory in 74% of 
the patients, requiring third-line agents and a median of 15 days staying in an intensive 
care unit. Focal motor and tonic–clonic seizures were observed in 90%, complex partial 
seizures in 14%, and myoclonic seizures in 14% of the cases. All patients showed T2/
FLAIR hyperintense foci in bilateral claustrum, appearing on average 10 days after SE 
onset. Other limbic (hippocampus, insular) alterations were present in 53% of patients. 
Within the personal cases, extensive search for known autoantibodies was inconclusive, 
though 7 of 11 patients had cerebrospinal fluid lymphocytic pleocytosis and 3 cases 
had oligoclonal bands. Two subjects died during the acute phase, one in the chronic 
phase (probable sudden unexplained death in epilepsy), and one developed a persistent 
vegetative state. Among survivors, 80% developed drug-resistant epilepsy. Febrile 
illness-related SE associated with bilateral claustrum hyperintensity on MRI represents 
a condition with defined clinical features and a presumed but unidentified autoimmune 
etiology. A better characterization of de novo SE is mandatory for the search of specific 
etiologies.
Keywords: new-onset refractory status epilepticus, claustrum, fever, status epilepticus, refractory status 
epilepticus, epilepsy
Abbreviations: AED, antiepileptic drugs; AERRPS, acute encephalopathy with repetitive refractory partial seizures; CSF, 
cerebrospinal fluid; FIRES, febrile infection-related epilepsy syndrome; FLAIR, fluid attenuation inversion recovery; ICU, 
intensive care unit; LGI1, leucine-rich glioma inactivated protein 1; NMDAR, N-methyl-d-aspartate receptor; NORSE, new-
onset refractory status epilepticus; PD, periodic discharges; SE, status epilepticus; RSE, refractory status epilepticus.
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inTrODUcTiOn
Status epilepticus (SE) is the second most common neurologic 
emergency (1). Up to 40% of SE cases are refractory status epilep-
ticus (RSE) to first- and second-line treatments (2, 3). New-onset 
RSE (NORSE) is a rare but challenging condition, characterized 
by the occurrence of a prolonged period of refractory seizures 
with no identifiable cause in otherwise healthy individuals (4–6). 
Gaspard et al. (7) reported a large retrospective case-series of 130 
NORSE cases evaluated between 2008 and 2013. In some patients, 
an autoimmune or paraneoplastic etiology was identified but 
more than half of the cases remained cryptogenic. Poor outcomes 
were observed in 62% of patients, while 22% of patients died. 
Therefore, improved knowledge of the electro-clinical features 
of NORSE, as well as identification of the underlying etiologies 
and best treatment options are mandatory. Anecdotal evidence 
suggests that immune-modulating therapies may be effective in 
SE (8) and in NORSE (9–11).
We recently described a small group of patients who devel-
oped NORSE several days after a febrile illness, all with a notable 
magnetic resonance imaging (MRI) sign characterized by T2 
signal alterations involving the bilateral claustrum (12). Several 
similar cases had previously been described, including several 
children with similar neuro-radiologic features, which were 
attributed to the spectrum of febrile infection-related epilepsy 
syndrome (FIRES) (13–15). Bilateral claustrum abnormalities 
were associated with medically intractable SE, focal motor sei-
zures, and myoclonic seizures. Diagnostic studies did not reveal 
an etiology in these cases.
This study aims to organize and better characterize the clini-
cal features of patients with NORSE and T2/FLAIR hyperintense 
foci in the bilateral claustrum on brain MRI by systematically 
reviewing the literature and describing newly reported personal 
cases. Increased awareness of this entity will be relevant in the 
management of patients with refractory SE.
MaTerials anD MeThODs
Information including demographic data, clinical features, diag-
nostic findings, therapeutic interventions, and clinical outcomes 
of patients fulfilling the following inclusion criteria were acquired: 
(a) previously healthy adults (>16 years of age) with refractory 
SE; (b) MRI evidence of bilateral hyperintense signal alteration 
of the claustrum on FLAIR/T2 imaging; and (c) no evidence of 
infectious agents in cerebrospinal fluid (CSF). Exclusion criteria 
were a previous history of seizures (febrile or afebrile), or a previ-
ous or current neurological disorder.
Patients’ data for cases 1–6 were collected and described in 
a previous publication (12), while for cases 7–12, data were col-
lected during the last 12 months.
Being a retrospective case collection, ethical approval was 
not required for this study in accordance with the national and 
institutional guidelines. Scientific advisory boards of participat-
ing institutions approved the study according to local regulations. 
Written informed consent was obtained from patients (for those 
surviving the SE), by their parents if underage, or by relatives in 
case of death during the acute phase. The three patients whose 
video we have included, as supporting information, gave their 
specific written consent for the brief video sequence of their typi-
cal seizures.
clinical and eeg evaluation
Data were collected retrospectively from the participating centers 
reviewing clinical charts, EEG, and video-EEG recordings (when 
available). RSE was defined as a SE episode that continues, regard-
less of the delay since the onset of the seizure, after failure of a 
trial of at least intravenous benzodiazepines and at least one AED, 
appropriately chosen and at adequate dosage. Thus, it required 
admission to the Intensive Care Unit (ICU) and the application 
of anesthetic drug therapy. Super-RSE (SRSE) was defined as 
SE that continues or recurs at least 24 h from the beginning of 
anesthetic therapy or recurs during the reduction or withdrawal 
of anesthesia (16).
laboratory investigations
All patients were examined for viral and bacterial infections. Viral 
DNA polyemerase chain reaction tests included HSV 1 and 2, 
HIV, varicella-zoster virus, HHV 6, cytomegalovirus, Epstein–
Barr virus, west nile virus, rubella, parvovirus B19, enterovirus, 
and mumps. Presence of oligoclonal IgG bands (OB) was assessed 
by means of isoelectro-focusing, performed with agarose gel sup-
port. A panel of autoimmune antibodies, including antinuclear 
antibodies, anti-phospholipid antibodies, anti-DNA antibodies, 
anti-cardiolipin antibodies, anti-extractable nuclear antigen anti-
bodies, and anti-thyroid antibodies were analyzed with immuno-
enzymatic tests and indirect immuno-fluorescent staining.
Computed tomography of the thorax and abdomen was per-
formed in all patients. An extensive blood analysis for classical 
onco-neural antibodies (anti-GAD, anti-Yo, Ri, Hu, anti-Ma2) 
was performed in all subjects, as well as testing for antibodies 
to N-methyl-d-aspartate receptor (NMDAR) (17), leucine-rich 
glioma inactivated protein 1 (LGI1), and contactin-associated 
protein-like 2 (Caspr2) (previously attributed to voltage-gated K 
channels) (18, 19).
Brain Mri
Patients underwent brain MRI studies with a field intensity of 
1.5 or 3 T during the acute phase and follow-up in the chronic 
phase of the illness. The median number of MRI per patient 
was four.
literature review
Searches for identification of studies were run from 1990 to 2016 
in MEDLINE and PubMed. Searches were limited from 1990 
to the present day since studies carried out previously would 
necessarily have included participants without MRI. The search 
keywords were: “FIRES”; “NORSE”; “status epilepticus” AND 
“claustrum”; “epilepsy” AND “claustrum”; “status epilepticus” 
AND “neuroimaging.” For each citation considered, the abstract 
was read (when available). The bibliography of each of the 
retrieved papers was examined to identify relevant references that 
could have been missed by electronic search. Only peer-reviewed 
original articles providing images of the claustrum involvement 
were accepted for inclusion in this article.
TaBle 2 | Magnetic resonance imaging (Mri) findings of personal and 
literature cases.
Reported cases (n) 31
Mri
Interval between fever onset and claustrum sign 
(days ± SD)
15.6 ± 7.2
Interval between SE onset and claustrum sign (days ± SD) 10 ± 6.4
Range between SE onset and claustrum sign (days) 3–25
Involvement of other structures (% of pts)
 Medial temporal lobe 33
 Thalamus (pulvinar) 3
 Cortex (insula) 27
SE, status epilepticus; pts, patients.
TaBle 1 | clinical and outcome data of personal and literature cases.
Reported cases (n) 31
Demographic data
Mean age (years ± SD) 24.6 ± 12.4
Age range (years) 7–65
Female gender (%) 55
Prodromal phase
Presence of fever (% of pts) 100
Interval between fever onset and SE onset (days ± SD) 6.1 ± 2.5
Altered mental status (% of pts) 63
Isolated seizures 27
acute phase
Seizures’ semiology (% of pts)
 Focal motor/s generalization 90
 Complex partial 14
 Myoclonus/e.p.c. 14
Response to treatments (% of pts)
 Responsive SE 26
 Refractory SE 32
 Super-refractory SE 42
Patients needing ICU (%) 74
Immuno-modulating therapies (% of pts)
 IV steroids 59
 IV Ig 48
 PEX 11
 None 26
 Undetermined 12.9
Outcomes
Death in acute phase (% of pts) 7
Death in chronic phase (% of pts) 4
Chronic epilepsy (% of pts) 78
Cognitive deficits (% of pts) 74
Behavioral deficits (% of pts) 32
SE, status epilepticus; pts, patients; e.p.c., epilepsia partialis continua; ICU, intensive 
care unit; IV, intravenous; Ig, immunoglobulin; PEX, plasma exchange.
Responsive SE indicates a response to first- and second-line antiepileptic drugs; 
refractory SE indicates patients who fail to respond to antiepileptic drugs requiring 
third-line agents (propofol, barbiturate anesthesia). Super-refractory SE indicates cases 
in which seizures recurred after one cycle of anesthetic treatment.
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resUlTs
Nineteen cases were retrieved from previous case-reports and 
series (13–15, 20–32), and 12 personal cases fulfilled the inclu-
sion criteria. Tables  1 and 2 summarize the main clinical and 
MRI findings of all 31 patients. Detailed descriptions of these 
cases can be found in the Supplementary Material (Tables S1–S3 
in Supplementary Material).
representative Patients
Case # 11
A 33-year-old woman presented to the emergency department 
with worsening confusion over 6  days in the setting of fever 
and malaise. Within hours of hospital admission she developed 
focal motor status with right facio-brachial clonic seizures with 
secondary generalization, originating from the left hemisphere 
electrographically. First- and second-line antiepileptic agents 
failed to control seizures, and she was transferred to the ICU. 
She developed independent seizures originating from the left 
and right hemispheres, clinically characterized by facial clonic 
twitching. During the acute phase of the disorder, she was treated 
with lacosamide, phenytoin, levetiracetam, and phenobarbital. 
Propofol and midazolam were used as third-line agents. She also 
received two cycles (5 days each) of intravenous immunoglobu-
lins (IVIG). Third-line agents were successfully weaned-off and, 
after 20 days in the ICU, the patient was finally discharged to the 
neurology unit and then home. Despite medication adjustments, 
with ultimate treatment with lacosamide 400bid and phenytoin 
300bid, she developed a chronic drug-resistant focal epilepsy 
with weekly seizures, and readmissions for breakthrough sei-
zures. Four months after presentation with SE, the patient showed 
deficits in short-term verbal and visuospatial memory, learning 
difficulties, and executive function problems. At 6  months she 
returned to her normal life with family support. Figure  1 is a 
schematic representation of the patient journey through the SE 
(see also Video S1 in Supplementary Material).
Case # 8
A 25-year-old man was admitted for evaluation of his first 
generalized tonic–clonic seizure after 5  days of fever, malaise, 
and headache. He soon developed very frequent, refractory focal 
seizures, originating either from the right (more commonly) 
or the left (less commonly) hemisphere. When the seizures 
where clinically observed, as many of them were subclinical, 
he demonstrated behaviors of confusion, staring, oral and hand 
automatisms, and occasional head version. Seizures were refrac-
tory to first- and second-line AEDs (including fosphenytoin, 
lacosamide, levetericetam, valproic acid, phenobarbital, and 
clonazepam), so he received third-line agents (propofol, mida-
zolam, and ketamine) in the ICU. He was treated with plasma 
exchange (five treatments over 9  days), finally resulting in an 
electro-clinical improvement. After a total of 30  days in the 
hospital, with 17 of those in the ICU, he was discharged to a 
rehabilitation facility. On discharge his neurological examination 
showed mild gait ataxia, limb dysmetria, with intermittently 
perseverative speech and hyper-religiosity. He was readmitted 
several times over the next year for breakthrough general-
ized tonic–clonic seizures or clusters of dyscognitive seizures 
described as behavorial arrest, leftward head deviation and dys-
tonic posturing of his left arm. EEG did not identify a consistent 
focus of onset for his seizures (at times bifrontal, right temporal, 
or left fronto-temporal). A fluorodeoxyglucose PET brain scan 
could not localize an epileptogenic focus. His MRI performed 
at 12  months from presentation demonstrated unchanged T2/
FLAIR hyperintense foci in the cerebral white matter in bilateral 
claustrum and external capsules, as well as progressive diffuse 
FigUre 2 | The “claustrum sign” in two patients. (a) Axial and coronal 
FLAIR sequence in case # 1, 29-year-old female, acquired 10 days after 
status epilepticus (SE) onset. (B) Axial and coronal FLAIR sequence in case # 
2, 24-year-old female, acquired 4 days after SE onset. Note the hyperintense 
appearance of the capsula esterna/claustrum region in the two cases.
FigUre 1 | schematic temporal evolution, procedures, and immuno-
modulating treatment in one patient (case # 11). IV Ig, intravenous 
immunoglobulins; CSF, cerebrospinal fluid; ICU, intensive care unit; RSE, 
refractory status epilepticus.
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cerebral volume loss. Despite many medication adjustments, the 
patient developed a chronic drug-resistant epilepsy, with his most 
recent antiepileptic regimen (listed in total daily doses) including 
clonazepam 6 mg, lacosamide 400 mg, levetiracetam 3,000 mg, 
phenobarbital 200  mg, valproic acid 3,500  mg. The overall 
seizure frequency did not improve on the modified Atkins diet. 
Subsequent treatment for refractory seizures with IVIG on two 
occasions, 1 month and again 3 months after his discharge for SE, 
did not result in clinical improvement. Ultimately at 1 year after 
initial presentation, he reported at least one focal dyscognitive 
seizure a week but had restarted physical activities such as weight 
lifting and swimming. Memory issues and daytime somnolence 
due to medications limited his ability to return to employment.
The Prodromal Phase
The patients affected by this condition are generally young 
(mean age at SE onset is 25 years; mode 29 years). A prodromal 
phase of fever with mild flu/cold symptoms or general malaise 
preceded SE by 6 days on average (ranging from 2 to 14 days) 
in all patients for whom we have these data (information is 
missing in 3 cases).
The acute Phase
In 63% of the reported cases, patients presented to the emergency 
room for sudden onset altered mental status, ranging from mild 
fluctuations in mental status to stupor. This could appear either 
as the only symptom (21 cases) or in combination with seizures 
(1 case), while 27% of the patients (8 patients) presented with sei-
zures only. In the early days, all personal cases were treated with 
antiviral and antibacterial drugs in the possibility of an infectious 
cause of the clinical picture and waiting for the laboratory results 
(negative in all patients, see Materials and Methods) on blood and 
CSF for infectious agents.
In regards to seizure semiology, 90% of patients had focal 
motor or tonic–clonic seizures, while 14% of patients had isolated 
complex partial seizures. One of the most striking characteristics 
in these cases is the extremely rapid evolution of seizure during 
the acute phase. For example the majority of patients presented 
with bilateral motor seizures (focal hemiclonic or multifocal myo-
clonic seizures with alternating affected side), which then could 
quickly evolve into a generalized non-convulsive or subtle/myo-
clonic SE. See supplementary videos (Video S1 in Supplementary 
Material, from case # 11; Video S2 in Supplementary Material, 
from case # 1; Video S3 in Supplementary Material, from case # 
7). Overall, 74% of patients rapidly developed a RSE/SRSE (RSE: 
32%; SRSE 42%), requiring admission to the ICU and anesthesia 
administration soon after initial presentation.
MRI Findings
As per inclusion criterion, the MRI during the acute phase, 
showed bilateral symmetric or asymmetric changes of the claus-
trum (so called “claustrum sign”) that appeared hyperintense 
on T2-weighed images (see Figures  2 and 3). On average, the 
claustrum sign was observed 10 days after SE onset (ranging from 
3 to 25 days). This finding was isolated to the claustrum in 13 
patients (43% of the cases), or it was part of a more extended 
signal hyperintensity alteration together with other limbic areas 
(see Table 2), including the insula (5 cases), the medial–temporal 
lobe (8 cases), the insula and medial–temporal lobe at the same 
time (2 cases), or the insula and other more diffuse cortical areas 
FigUre 3 | The “claustrum sign” in four patients. (a) Axial T2 sequence in case # 8, 25-year-old male, acquired 15 days after status epilepticus (SE) onset. (B) 
Axial FLAIR sequence in case # 10, 19-year-old female, acquired 6 days after SE onset. (c) Axial T2 image in case # 11, 33-year-old female, acquired 21 days after 
SE onset. (D) Axial FLAIR image in case # 7, 38-year-old female, acquired 25 days after SE onset. Note the hyperintense appearance of the capsula esterna/
claustrum region in the four cases. Despite the different MRI scanner and image parameters, the hyperintensity of the claustrum is easily recognizable in each case. 
The exact location and extension of the signal alteration varies across the four cases. In all patients is present a bilateral involvement. Note the signal alteration 
extending to the insular/peri-insular cortex and subcortical white matter in panel (D).
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(1 case). The alteration involving the medial temporal region 
consisted in bilateral hyperintensity of the amygdala/hippocam-
pus. In one case, the bilateral claustrum was seen together with a 
unilateral pulvinar hyperintensity.
For the 12 newly described personal cases, a follow-up MRI 
study was obtained at various points after resolution of SE. In all 
but one case, the claustrum alterations disappeared after resolu-
tion of SE, and in one case the claustrum sign disappeared during 
ongoing SE. Follow-up MRI showed a variable degree of atrophy, 
ranging from very mild to severe and diffuse. Bilateral volume 
reduction of the hippocampus was present in four cases, always 
concomitantly with cortical atrophy.
EEG Findings
The characteristics of the EEG are defined only for the 12 personal 
cases. Eight out of 12 patients were monitored by continuous EEG 
(cEEG; meaning a continuous EEG recording of longer duration 
of 8 h per day). In four subjects, shorter and periodic EEG record-
ings were performed on clinical needs. On average, patients were 
monitored for 22 days (range: 3–90 days). Seizures were recorded 
in each case (>100 in seven patients; >20 in five). The most 
striking pattern was the presence of periodic discharges (PD) 
(either generalized, bilateral independent, or lateralized). Often 
in different period of SE evolution the pattern changed so that 
different types of PD were observed in each case. Generalized PD 
were observed in five cases; lateralized unilateral PD were present 
in five; bilateral independent or multifocal PD were observed in 
11 cases (see Figures 4–6).
Laboratory Investigations
Cerebrospinal fluid samples are available in 11 of the personal 
cases. A mild lymphocytic pleiocytosis (5–40 cells) was pre-
sent in 7 cases and oligo-clonal bands were observed in three. 
Among all these cases, the CSF autoantibodies panel was nega-
tive (see Table S2 in Supplementary Material) and the etiology 
remains cryptogenic. Among the previously published cases, 
one had positive anti-VGKC antibodies and in two cases there 
were signs of a recent virus infection (mumps in one case 
and HSV1 in the other one) without any sign of a direct CNS 
involvement.
Immune-Modulating Treatments
Besides antiepileptic drugs and anesthetic therapy, 20 out of 27 
patients (74%) received immunotherapy (for five literature cases, 
these data are lacking). High dose intravenous steroids were used 
in 59% of the patients; intravenous immune-globulins were used 
in 48% of patients, and plasma exchange in 11%.
The chronic Phase and Outcomes
Two patients died during their initial hospitalization. Another 
patient died 2 years later, and his death was defined as a prob-
able sudden unexplained death in epilepsy. Eighteen out of 
23 patients (78%) developed a chronic focal epilepsy, mostly 
resistant to medical therapy. Moreover, 65% of the patients 
developed cognitive deficits. These deficits were reported to be 
mild for 60% and moderate to severe for 40% of these patients. 
Finally, 32% of patients ultimately were left with behavioral 
alterations (impulsivity, psychosis, episodes of aggression, anxi-
ety). Overall, only 32% of the patients returned to their clinical 
baseline condition.
DiscUssiOn
New-onset refractory status epilepticus represents a challenging 
entity. Only in recent years, it has begun to shed light on these 
cases, showing that a significant portion has an autoimmune and/
or paraneoplastic etiology. The aim of this report is an attempt 
to define a group of patients that we believe share a constellation 
of symptoms, EEG, and MRI findings. In 2015, we previously 
described six patients presenting with a refractory SE after a febrile 
illness and a striking signal alteration involving the region of the 
claustrum on brain MRI (12). In last 12  months, we collected 
FigUre 4 | eeg evolution in case # 1. (a) EEG during the initial hours of status epilepticus (SE). The patient was awake but confused with sub-continuous 
myoclonic jerks involving predominantly left limbs. The last channel records the surface EMG activity from the left anterior tibialis muscle. The EEG traces show a 
general slowing of the background activity, more evident on the right hemisphere, where periodic sharp complex are evident, often time-locked with myoclonic jerks. 
(B,c) EEG during the evolution in refractory SE, in the from of a myoclonic SE. The patient is under general anesthesia with barbiturates plus antiepileptic drugs 
poly-therapy. (D) Represents the EEG evolution during recovery. EEG recording parameters: high-pass filter: 0.3 Hz; low-pass filter 50 Hz. EMG parameters: 
high-pass filters 50 Hz; low-pass filter 250 Hz. Sampling frequency 1,024 Hz.
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new cases with similar clinical histories and imaging findings 
(“the claustrum sign”). The claustrum sign was associated with 
an aggressive refractory form of SE. The temporal evolution of the 
clinical picture was very well defined. First, patients experienced 
a prodromal phase characterized by fever and altered mental 
status, followed by an acute phase with focal motor, tonic–clonic, 
and myoclonic seizures, often with refractory SE requiring ICU 
admission and anesthetic drugs, followed by a chronic phase 
with the development of a focal drug-resistant epilepsy in 80% 
of surviving patients. The T2/FLAIR hyperintensity of the claus-
trum/capsula externa region was bilateral, though sometimes 
asymmetric, in every case, and in half of the cases extended into 
the insular cortex and the medial temporal lobe region as well. We 
confirmed that these alterations follow the onset of the status by 
an average of 10 days and resolved over the followings weeks in 
the majority of patients. It is unclear if these findings are a conse-
quence of ictal activity or a reflection of a pathogenic mechanism 
affecting the same bilateral brain networks. All but one of the 
patients experienced complete resolution of the MRI abnormali-
ties, with one patient demonstrating resolution during ongoing 
SE, while one patient showed the persistence of hyperintense foci 
on a 12-month follow-up MRI. Probably, only future prospective 
studies, with the use of MRI at standardized time-points respect 
with SE onset, will be able to elucidate the role and mechanisms 
underlying this imaging sign.
Regarding, the possible etiology of this condition we were 
unable to identify a specific causative antibody for known autoim-
mune syndromes. CSF samples showed lymphocytic pleiocytosis 
and oligo-clonal bands, which supports a role for the immune 
system in the pathophysiology of this condition. Additionally, 
patient improvement with immunomodulatory treatment could 
support this hypothesis. Beside this speculative consideration, it 
is, however, important to recognize that at present no definite 
etiology was reliably demonstrated, and even if we excluded sev-
eral possible infectious conditions, the possibility of an unknown 
infectious agent, as causative of the reported NORSE cases cannot 
be completely ruled-out. More remote seems the possibility of 
drug intoxication for the presented patients: no one had a history 
of drug abuse or psychiatric comorbidities; no one had possible 
exposure to possible environmental toxic substances. Given that, 
we agree with previous literature that as for the actual knowledge 
(and its limits) it is advisable to rapidly treat these patients with 
immune modulatory agents, beyond just the standard treatment 
of SE (7, 9–11).
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From the electro-clinical point of view, a very aggressive form 
of SE was observed in the majority of the patients. The physiologi-
cal properties of the claustrum can be important to explain this 
particular evolution. Indeed, the claustrum could be a key region 
in promoting the propagation and synchronization of abnormal 
epileptic activity from several cortical regions (12, 32). Two prop-
erties of claustrum neurons are relevant: (a) claustro-cortical fib-
ers connect the claustrum with several cortical areas including the 
prefrontal, pre-postcentral, orbitofrontal, and medial temporal 
cortex (33, 34); (b) the claustrum is constituted by densely packed 
and tightly interconnected GABAergic interneurons whose dam-
age could promote a state of hyper-synchronization and bindings 
of activity from several distant cortical regions (34–38). Notably, 
these experimental findings can account for the frequently 
observed presence of PD over one or both hemispheres during 
continuous EEG monitoring in our patients, as well as the often 
bi-hemispheric or independent seizure origin during the acute 
phase. Moreover, the involvement of the claustrum/insular cortex 
explains also the frequent involvement of the oro-facial muscles 
(see videos in Supplementary Material). Indeed, the involvement 
of this body region is not surprising considering a probable ictal 
involvement of the adjacent fronto-opercular cortex, controlling 
the oro-facial movements.
Finally, concerning the outcomes and the chronic phase, we 
confirmed that a very high proportion (about 80%) of the patients 
developed a chronic epilepsy. In this respect, we cannot say if 
epilepsy during the chronic phase is the consequence of an epi-
leptogenic process related to the SE or rather if chronic epilepsy 
is the consequence of a persistently “active” etiological factor. 
Surely, in the majority of the patients, the epilepsy observed dur-
ing the chronic phase was drug-resistant, with multiple seizures 
per month. Notably, one of the patients died 2  years after SE 
termination due to cardio-respiratory arrest after a suspected 
tonic–clonic seizure during sleep.
conclusion
Febrile illness-related SE with claustrum hyperintensity repre-
sents a condition with defined clinical features. We hope that 
FigUre 5 | representative seizure in case # 7. (a) Periodic theta burst involving the right fronto-temporal leads evolving into a right ictal rhythmic discharge (*) 
and then in a diffuse EEG “flattening” (**). (B) Diffuse EMG artifacts during the tonic–clonic phase of the seizures. (c) Terminal part of the seizures with predominant 
involvement of the left fronto-temporal region. In each panel, the EMG trace is recorded from the orbicularis oris muscle. EEG recording parameters: high-pass filter: 
0.3 Hz; low-pass filter 50 Hz. EMG parameters: high-pass filters 50 Hz; low-pass filter 250 Hz. Sampling frequency 1,024 Hz.
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future studies will help to better understand the pathophysiology 
and the etiology of this condition that at present remains specu-
lative, though a probable autoimmune mechanism is suspected. 
Prospective, multi-centric, studies on NORSE are mandatory to 
answer several open questions on this condition.
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